10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,316 shares of the company’s stock after selling 1,461 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in 10x Genomics were worth $1,081,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. UMB Bank n.a. lifted its stake in 10x Genomics by 51.6% during the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after purchasing an additional 266 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in 10x Genomics during the third quarter worth approximately $146,000. Bleakley Financial Group LLC purchased a new stake in 10x Genomics during the fourth quarter worth approximately $234,000. Simplicity Solutions LLC purchased a new stake in 10x Genomics during the fourth quarter worth approximately $234,000. Finally, AXQ Capital LP purchased a new stake in 10x Genomics during the third quarter worth approximately $280,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $49.53, for a total value of $49,530.00. Following the transaction, the chief executive officer now owns 855,381 shares of the company’s stock, valued at $42,367,020.93. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $49.53, for a total value of $49,530.00. Following the transaction, the chief executive officer now owns 855,381 shares of the company’s stock, valued at $42,367,020.93. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Justin J. Mcanear sold 1,865 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $86,424.10. Following the completion of the transaction, the chief financial officer now directly owns 95,240 shares in the company, valued at approximately $4,413,421.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,959 shares of company stock valued at $592,806. Company insiders own 10.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on TXG shares. Deutsche Bank Aktiengesellschaft decreased their target price on 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. Stifel Nicolaus decreased their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Finally, Barclays decreased their target price on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has an average rating of “Moderate Buy” and a consensus price target of $60.22.

10x Genomics Trading Up 2.6 %

Shares of NASDAQ TXG opened at $27.59 on Friday. 10x Genomics, Inc. has a twelve month low of $26.30 and a twelve month high of $63.57. The stock has a 50 day moving average of $37.70 and a two-hundred day moving average of $42.53. The stock has a market cap of $3.29 billion, a P/E ratio of -12.71 and a beta of 1.90.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). The firm had revenue of $183.98 million during the quarter, compared to analysts’ expectations of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. 10x Genomics’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.15) EPS. As a group, research analysts predict that 10x Genomics, Inc. will post -1.47 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.